BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Summary by AI BETAClose X

BioNTech has commenced a public exchange offer to acquire all outstanding shares of CureVac N.V. CureVac shareholders will receive approximately $5.46 in BioNTech American Depositary Shares for each CureVac share, implying an aggregate equity value for CureVac of approximately $1.25 billion, subject to adjustments based on a collar mechanism. The exchange ratio will vary between 0.04318 and 0.06476 of a BioNTech ADS per CureVac share, depending on BioNTech's ADS volume-weighted average price. The offer is scheduled to expire on December 3, 2025, unless extended or terminated earlier. BioNTech aims to acquire at least 80% of CureVac’s shares, a threshold that may be reduced to 75% under certain circumstances.

Disclaimer*

UK 100

Latest directors dealings